Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism

被引:70
|
作者
King, BP [1 ]
Khan, TI [1 ]
Aithal, GP [1 ]
Kamali, F [1 ]
Daly, AK [1 ]
机构
[1] Univ Newcastle Upon Tyne, Sch Med, Sch Clin & Lab Sci, Pharmacogenet Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源
PHARMACOGENETICS | 2004年 / 14卷 / 12期
关键词
CYP2C9; warfarin; polymorphism; upstream sequence; cytochrome P450; haplotype;
D O I
10.1097/00008571-200412000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives To assess whether CYP2C9 alleles other than CYP2C9*2 and *3 are associated with a low-warfarin dose requirement and the relevance of upstream CYP2C9 polymorphisms to dose requirement and metabolism. Methods CYP2C9 exons, intron-exon boundaries and 3 kb of upstream sequence in 20 patients requiring less than or equal to 1.5 mg warfarin per day and with apparently homozygous wildtype or heterozygous CYP2C9*2 genotypes were screened for novel polymorphisms by single-strand conformational polymorphism analysis. PCR-based genotyping assays for novel upstream and other known polymorphisms were used to screen a larger patient population of known CYP2C9*2 and *3 genotype requiring a range of warfarin doses. Results Polymorphisms at eight different upstream sites were found, five of which were already described. We found that the majority of the upstream polymorphisms were in complete linkage disequilibrium with previously described coding region polymorphisms. However, two polymorphisms, T-1188C and the novel DeltaG-2664DeltaT-2665, occurred both in individuals who were otherwise wild-type and in individuals positive for coding region polymorphisms. Evidence for 11 haplotypes, including 8 with frequencies greater than or equal to 0.01, was obtained. In individuals negative for coding region polymorphisms, neither individual genotypes for T-1188C or DeltaG-2664DeltaT-2665 or particular combinations of haplotype pairs were predictive of dose requirement or S-warfarin total clearance, suggesting neither upstream polymorphism was functionally significant. Dose requirements in CYP2C9*11 heterozygotes were not statistically significantly different from homozygous wild-type individuals. Conclusions The coding region non-synonymous polymorphisms associated with the CYP2C9*2 and CYP2C9*3 alleles are the major CYP2C9-related factor affecting warfarin dose in UK Caucasians. Upstream CYP2C9 polymorphisms do not appear to be important independent determinants of dose requirement. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:813 / 822
页数:10
相关论文
共 50 条
  • [1] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism
    King, BP
    Khan, TI
    Kamali, F
    Daly, AK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 639 - 639
  • [2] Warfarin dose requirement and CYP2C9 polymorphisms -: Reply
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    LANCET, 1999, 353 (9168): : 1972 - 1973
  • [3] The influence of coagulation factor and CYP2C9 polymorphisms on warfarin dose
    Aquilante, CL
    Yarandi, HN
    Langaee, TY
    Tromberg, JS
    Lopez, LM
    Waddell, CD
    Johnson, JA
    CIRCULATION, 2003, 108 (17) : 424 - 424
  • [4] CYP2C9 genetic polymorphisms and warfarin
    Redman, AR
    Dickmann, LJ
    Kidd, RS
    Goldstein, JA
    Ritchie, DM
    Hon, YY
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (02) : 149 - 154
  • [5] Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms
    Mark W. Linder
    Stephen Looney
    Jesse E. Adams
    Nancy Johnson
    Deborah Antonino-Green
    Nichole Lacefield
    Bonny L. Bukaveckas
    Roland Valdes
    Journal of Thrombosis and Thrombolysis, 2002, 14 : 227 - 232
  • [6] Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements
    King, BP
    Khan, T
    Kamali, F
    Daly, AK
    DRUG METABOLISM REVIEWS, 2003, 35 : 133 - 133
  • [7] Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
    Linder, MW
    Looney, S
    Adams, JE
    Johnson, N
    Antonino-Green, D
    Lacefield, N
    Bukaveckas, BL
    Valdes, R
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2002, 14 (03) : 227 - 232
  • [8] Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9
    Khaleqsefat, E.
    Khalaj-Kondori, M.
    Bonyadi, Jabbarpour M.
    Battaloglu, E.
    HIPPOKRATIA, 2017, 21 (02) : 93 - 96
  • [9] CYP2C9 Polymorphisms are associated with warfarin anticoagulation-dose requirements
    潘耀东
    李胜军
    河南外科学杂志, 2011, (06) : 1 - 2
  • [10] Analysis of CYP2C9 polymorphisms (*2 and*3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR
    Yasmeen, Faiza
    Ghafoor, Muhammad Bilal
    Khalid, Abdul Wadood
    Latif, Waqas
    Mohsin, Shahida
    Khaliq, Shagufta
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 40 (02) : 218 - 224